[{"from": "human", "value": "Could you provide a description of this molecule? [C][N][Branch1][C][C][C][/C][=C][/C][=Branch1][C][=O][N][C][=C][Branch2][Ring1][S][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=Branch1][=Branch1][=N][C][=N][Ring1][#Branch1][N][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][Cl][O][C@H1][C][C][O][C][Ring1][Branch1]"}, {"from": "gpt", "value": "The molecule is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim."}]